[Skip to content]

  • High Contrast
  • High Contrast
  • Normal Contrast
George Eliot Hospital - NHS Trust
Search our Site
Advanced Search How To Find Us

Research and Development

Contact details

Do You want to get involved in Research  at George Eliot Hospital?

Write to us:

Research and Development Office

Door #88/124, 1st Floor Pathology Lab

College Street



CV10 7DJ

Email us:

For any queries relating to patient involvement and events please contact: Research@geh.nhs.uk

For any sponsorship, governance, research funding and grant queries please contact: Research@geh.nhs.uk

Phone us:

R&D Office:

024 7615 3426 or 024 7686 5512

Diabetes Research Office

024 7686 5358 or 024 7615 3592

Updated December 2021

R & D Director

Name: Prof Simon Brake

E-mail: Simon.brake@geh.nhs.uk

Secretary: N/A

Judith Lake

Research and Development Manager

Email: judith.lake@geh.nhs.uk

Tel: 024 7615 3426

Kirsty Fincham, Research Governance Officer

Email: kirsty.fincham@geh.nhs.uk

Specialty details

George Eliot Hospital NHS Trust is committed to supporting research to provide the very best care for its patients. Research is important to develop new treatments and improve the way we care. Patients may be asked if they wish to take part in a study when they visit the hospital.

There are a wide range of research studies available, from simple questionnaires to drug studies. 

We currently have studies looking at:




Heart disease

Studies in other disease areas may also be available.  If you are interested in research, please feel free to ask a member of staff if there are studies available for you. Participation is voluntary, and patients who do not wish to take part will continue to receive the best care we are able to offer.

All research being conducted at George Eliot Hospital NHS Trust has been reviewed by the research department and a research ethics committee to ensure every study is of the very best standard.

National Targets for research

George Eliot Hospital NHS Trust is measured against two national targets to improve the way it conducts research. 

These are:

Initiation – it should take no more than 70 days to receive consent from a patient after a researcher has provided their study paperwork to the R&D department.

Delivery – we should have the number of patients consented into a trial within the timeline we agreed at the start of the study.

You can see how we are performing here - Performance and initiation research and performance and delivering research Q1-Q4 20-21 and Q1 21-22

Our performance is comparable with other Trusts. We are actively looking at innovative new ways to improve the way we deliver research.

Research and Development

Covid 19 Information

Since the COVID-19 pandemic started, the Research and Development team have suspended recruitment and follow-up to all non-COVID 19 studies and have concentrated on recruiting patients into DHSC approved COVID-19 studies.  At the moment there are 5 studies open for patients to enter:

Clinical characterisation protocol for severe emerging infection (also called ISARIC) – this is a data collection study and the information gained from it is being used to monitor the course of the illness and to inform Government; 350 patients have entered the study from GEH. 

RECOVERY (randomised evaluation of COVID-19 therapy) – an interventional study testing potential treatments for COVID-19; 27 patients have been recruited from GEH.  This study has been mentioned in the media a number of times and nationally has recruited 9,500 patients.

Pandemic influenza in pregnancy – data is collected from COVID-19 positive pregnant women and will be used to inform guidance for women and maternity staff: 2 patients have entered the study from GEH.

GenOMICC study (Genetics of susceptibility and mortality in critical care) - has recruited 2 patients.  The study aims to identify the specific genes that cause some people to be susceptible to specific infections (e.g. COVID-19). Identifying the genes that cause susceptibility may help to prioritise treatments to respond to the global crisis.

REMAP-CAP - The goal is to generate evidence that can be applied during the pandemic to reduce death rates or reduce the length of admission to intensive care and is for patients who are severely ill. Each patient entering the study can be randomised to several different combinations of treatment at once.  This study opened on 11/5/20 and so far there have not been any patients ill enough to enter the study.

Latest News

New partnership to sequence human genomes in fight against coronavirus

Thousands of patients severely ill with coronavirus will have their genetic code studied to help scientists understand whether a person’s genetics may influence their susceptibility to the virus.

New partnership to sequence human genomes in fight against coronavirus